Gregory D. Gorgas has served as our President, Chief Executive Officer and on our board of directors since April 2017. He holds three decades of successful drug development and commercialization experience in both pharmaceutical corporations and biotech companies, including more than a dozen product launches, four of which were first-in-class. Before leading Artelo, Mr. Gorgas served as Senior Vice President, Commercial and corporate officer at Mast Therapeutics, a publicly held biotechnology company, where he had commercial leadership accountability and business development responsibilities for the hematology, oncology and cardiovascular programs. Previously, Mr. Gorgas was Managing Director at Theragence, a privately held company he co-founded, that provides superior drug development insights through the application of proprietary computational intelligence data mining tools. Prior to that, Mr. Gorgas worked at Biogen, a publicly held biotechnology company, as Senior Director, Global Marketing with responsibility for the strategic vision and operational commercialization of the company’s worldwide cancer business. Previously he held leadership positions of increasing responsibility with IDEC Pharmaceuticals, Chiron, Cetus and Upjohn, all publicly held companies. Mr. Gorgas currently serves as member of the board of directors at Theragence and on the advisory board of Klotho Therapeutics. Mr. Gorgas earned a BA in economics from California State University, Northridge and, from the University of Phoenix, an MBA.
Steven D. Reich, MD has served as our Chief Medical Officer since April 2018. Dr. Reich brought to Artelo over four decades of drug research experience, both as an academically based investigator for Phase I-III trials and as a senior leader in the biopharma industry where he designed and managed Phase I-IV trials. He has directed studies with sites in North America, Europe, and Asia. Dr. Reich’s managerial experience includes directing multinational medical research groups within pharmaceutical and biotechnology companies and at a contract research organization. He headed the clinical research programs which led to five US, one Canadian, and two European drug approvals, and he was a team member for multiple other international approvals, primarily anti-cancer drugs. Dr. Reich received his MD degree at the New Jersey College of Medicine and Dentistry and a diplomate certification from the American Board of Internal Medicine, with a sub-specialty of Medical Oncology. Dr. Reich was a clinical fellow at the Baltimore Cancer Research Center NCI, NIH, Baltimore, MD.
Peter O’Brien is a co-founder of Artelo Biosciences, head of our European operations, and serves on the board of directors. He has been in the recruitment industry since 2004, founding his own successful recruitment firms, Driver & Labour Recruit and Hanrahan & O`Brien Consultants in 2005. After Mr. O’Brien sold his position in 2006. In 2008 Mr. O’Brien worked for HSBC International in Jersey, Channel Islands, UK, in the Private Client space. In 2012 he founded Nursing Station, a company focused on the recruitment and placement of Nurses in healthcare throughout Ireland and the UK. Medacs Healthcare under the Impellam Group Plc acquired Nursing Station in July of 2016. Peter founded the very successful Medical Job board www.MedicalstaffIreland.com in 2015, Mr. O’Brien graduated from Griffith College, Cork 2004 with a Diploma in Marketing, Sales, PR and Advertising.